Judgment — ECLI:EU:T:2018:330
Date: 2018-06-06
Language of the case: English
Court formation: Sixth Chamber
Subject matter: Trade marks;Intellectual, industrial and commercial property
Procedure: Action for annulment - successful
Origin: United Kingdom

Judgment of the General Court of 6 June 2018 — Glaxo Group v EUIPO — Celon Pharma (SALMEX) (Case T-803/16) 1 (EU trade mark — Invalidity proceedings — EU figurative mark SALMEX — Earlier three-dimensional national mark — Competence of the Board of Appeal to examine of its own motion whether the earlier mark had been put to genuine use — Article 64(1) and Article 76(1) of Regulation (EC) No 207/2009 (now Article 71(1) and Article 95(1) of Regulation (EU) 2017/1001)) Language of the case: English Parties Applicant: Glaxo Group Ltd (Brentford, United Kingdom) (represented by: S. Baran, T. St Quintin, S. Wickenden, Barristers, E. Morris and R. Jacob, Solicitors) Defendant: European Union Intellectual Property Office (represented by: D. Hanf, acting as Agent) Other party to the proceedings before the Board of Appeal of EUIPO, intervener before the General Court: Celon Pharma S.A. (Łomianki, Poland) (represented by: M. Krasiński, lawyer) Re: Action brought against the decision of the Fourth Board of Appeal of EUIPO of 31 August 2016 (Case R 2108/2015-4) relating to invalidity proceedings between Glaxo Group Ltd and Celon Pharma. Operative part of the judgment The Court: Annuls the decision of the Fourth Board of Appeal of the European Union Intellectual Property Office (EUIPO) of 31 August 2016 (Case R 2108/2015-4); Orders EUIPO to bear its own costs and those incurred by Glaxo Group Ltd during the proceedings before the General Court; Orders Celon Pharma S.A. to bear its own costs relating to the proceedings before the General Court. ____________ 1 OJ C 22, 23.1.2017.